Aptevo Therapeutics

APVO · Nasdaq · United States

Share price · APVO

$0.45-2.45 (-84.62%) 3M

close as of 2026-11-18 · 24h delayed · vol 637K (7.6x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when APVO's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 17 Nov 2026-16.0%
  2. 11 Nov 2026-29.6%
  3. 27 Oct 2026-14.7%
  4. 3 Sep 2026-34.2%
  5. 2 Sep 2026+11.1%

    Nothing announced by APVO that day or the session before.

  6. 14 Aug 2026-13.5%
  7. 12 Aug 2026-15.4%

    Nothing announced by APVO that day or the session before.

  8. 21 Jul 2026-7.0%

    Nothing announced by APVO that day or the session before.

  9. 14 Jul 2026+11.3%
  10. 9 Jul 2026-12.4%

    Nothing announced by APVO that day or the session before.

Share of unusual movement by asset

For each asset, the share of APVO's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Mipletamig
events and moves
89%
Other company news (earnings, financing, releases naming no asset)—28%
Sessions with no dated event—63%

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
ALG.APV-527No recent activity
Phase 1/2
4-1BB (CD137) x 5T4Multispecific antibody
Solid Tumors
Phase 1
CD123 x CD3Biologic (subtype unspecified)
Acute Myeloid Leukemia

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (15)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$3.7M$9.8M$6.4M-$5.5M operating cash flowreport ↗
View 14 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1——$15M—report ↗
2025-Q3—$4.0M$21M$7.5M-$6.7M operating cash flowreport ↗
2025-Q2—$3.3M$9.4M$6.2M-$7.1M operating cash flowreport ↗
2025-Q1—$3.6M$2.1M$6.4M-$6.6M operating cash flowreport ↗
2024-Q3—$3.1M$7.8M$5.1M-$5.2M operating cash flowreport ↗
2024-Q2—$3.6M$8.1M$5.9M-$6.2M operating cash flowreport ↗
2024-Q1—$3.8M$10M$6.8M-$6.7M operating cash flowreport ↗
2023-Q3—$3.9M$19M$6.3M-$6.2M operating cash flowreport ↗
2023-Q2—$5.5M$21M$8.0M-$4.8M operating cash flowreport ↗
2023-Q1—$4.2M$25M—$4.6M operating cash flowreport ↗
2022-Q3—$4.5M$22M$7.6M-$6.9M operating cash flowreport ↗
2022-Q2—$3.9M$29M—-$3.1M operating cash flowreport ↗
2022-Q1$3.1M$4.9M$35M$7.7M-$5.1M operating cash flowreport ↗
2021-Q3$3.1M$4.4M$52M$7.0M-$5.2M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$15M$22M$6.5M-$26M operating cash flowreport ↗

Aptevo Therapeutics reported no revenue for FY2025, with prior-year revenue also not disclosed. R&D expense was $14.54M, up 1.1% YoY from $14.38M. Cash and equivalents totaled $21.62M, and the company posted a net loss of $25.97M and a quarterly net burn of $25.97M.

Management stated current resources are expected to support operations into the fourth quarter of 2026, while a $60M equity line facility established in 2026 could, if fully utilized, extend support into 2029. Updated mipletamig data from 28 frontline AML patients showed an 86% clinical benefit rate with no cytokine release syndrome, and the company expanded its CD3 pipeline with three new multispecific candidates, including its first two trispecific assets. Additionally, Marvin White is transitioning to Executive Chair, with Jeff Lamothe assuming the roles of President and Chief Executive Officer.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$14M$8.7M$6.0M-$24M operating cash flowreport ↗
2023-FY—$17M$17M$4.3M-$12M operating cash flowreport ↗
2022-FY$3.1M$18M$23M—-$21M operating cash flowreport ↗
2021-FY$12M$19M$45M$7.1M-$22M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-08-06Niederhuber John · directorOption exercise400——Form 4
2026-08-06Kunz Barbara Lopez · directorOption exercise400——Form 4
2026-08-06Abdun-Nabi Daniel · directorOption exercise400——Form 4
2026-08-06Grant Grady III · directorOption exercise400——Form 4
2026-08-06Huebner Dirk · SVP, CMOOption exercise638——Form 4
2026-08-06Kwon SoYoung · SVP, GC, BD & Corp AffairsOption exercise638——Form 4
2026-08-06Taylor Daphne · SVP, CFOOption exercise638——Form 4
2026-08-06Lamothe Jeffrey G. · director, President and CEOOption exercise961——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 9 reporting institutions held 0.1M shares ($146K, 3.0% of shares outstanding).

#InstitutionSharesValue
1GEODE CAPITAL MANAGEMENT, LLC13,337$57K
2VANGUARD CAPITAL MANAGEMENT LLC12,713$54K
3VANGUARD FIDUCIARY TRUST CO4,142$18K
4UBS Group AG3,445$15K
5OSAIC HOLDINGS, INC.360$2K
6SBI Securities Co., Ltd.109$465
7GSA CAPITAL PARTNERS LLP19,638$84
8CWM, LLC5$21
9DANSKE BANK A/S1$4